Holen Sie sich die Stockscreener-App
192.55
0.23%
-0.4282
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ILMN?
Forum
Prognose
Aktiensplit
Illumina Inc Aktie (ILMN) Neueste Nachrichten
Standard BioTools Announces Sale of Mass Cytometry Business and Illumina's Buyout of Contingent Payments to Advance Merger with Treeline Biosciences - Investing News Network
Standard BioTools (NASDAQ: LAB) nets $30M Illumina buyout, sells mass cytometry arm - Stock Titan
Standard BioTools Sells Mass Cytometry Unit for $5 Million Note and Nets $30 Million From Illumina - TradingView
(ILMN) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Illumina Inc. stock underperforms Monday when compared to competitors - MarketWatch
ILMN|Illumina Inc|Price:189.380|Chg%:-4.710 - TradingKey
Illumina Inc (ILMN) Income Statement - TradingKey
ILMN|Illumina Inc|Price:194.090|Chg%:-2.770 - TradingKey
Illumina Inc (ILMN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Illumina stock trades steady as investors weigh restructuring and recovery prospects - Ad-hoc-news.de
Illumina, Inc. Revenue Breakdown – BIVA:ILMN - TradingView
Illumina Inc (ILMN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Illumina Inc. stock underperforms Friday when compared to competitors - MarketWatch
Illumina, Inc. Revenue Breakdown – BOATS:ILMN - TradingView
Blood Transfusion Diagnostics Market Size to Hit USD 8.67 Billion by 2035 as Automated Testing and AI-Driven Blood Safety Solutions Accelerate Growth | SNS Insider - GlobeNewswire Inc.
Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK) and Illumina (ILMN) - The Globe and Mail
Illumina Inc (ILMN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
ILMN5150650 Bond Profile — Key Metrics - TradingView
Illumina stock trades steady as investors weigh Q1 2026 recovery and gene sequencing demand - Ad-hoc-news.de
Illumina stock hits 52-week high at 197.49 USD By Investing.com - Investing.com Australia
Illumina stock hits 52-week high at 197.49 USD - Investing.com UK
Illumina Inc (ILMN) Shares Surge 3.1% -- What GF Score of 72 Tel - GuruFocus
Illumina Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
ILMN6231083 Bond Profile — Key Metrics - TradingView
Illumina stock surges 90% after InvestingPro Fair Value spotted opportunity By Investing.com - Investing.com
ILMN|Illumina Inc|Price:197.110|Chg%:+0.250 - TradingKey
Illumina stock holds after a 2025 revenue rebound - Ad-hoc-news.de
Illumina stock trades steady as investors weigh Q1 2026 revenue decline and cost-cutting plan - Ad-hoc-news.de
Is Illumina Inc (ILMN) Overvalued After 4.2% Rally? GF Value Say - GuruFocus
Illumina Inc. stock outperforms competitors on strong trading day - MarketWatch
Lobbying Update: $300,000 of ILLUMINA INC. lobbying was just disclosed - Quiver Quantitative
Geraldine Bliss wants parents to ask, “Could it be genetic?” - Illumina
Illumina stock holds as investors await the next report - Ad-hoc-news.de
Eli Lilly (LLY) Joins Illumina Atlas To Map Disease With AI - Yahoo Finance
ILUB Bond Profile — Key Metrics - TradingView
Illumina stock edges higher as investors weigh Q1 2026 results and genomics demand - Ad-hoc-news.de
Wall Street Just Pushed Illumina Targets to $200. Here’s Where the Stock Could Go - TIKR.com
Illumina stock steadies as investors weigh going concern warning and turnaround plan - ad-hoc-news.de
Illumina stock trades on earnings context after recent guidance - ad-hoc-news.de
Illumina (ILMN) Expands Billion Cell Atlas Alliance With New AI Drug Discovery Members - Sahm
Illumina expands Billion Cell Atlas alliance with Formation Bio, adds two other AI drug developers - Bitget
Daniel M. Skovronsky, MD, PhD, appointed to Illumina's Board of Directors - Illumina
Illumina launches StrataMap Spatial Solution, a powerful end-to-end spatial whole transcriptome research solution - Illumina
Illumina (ILMN) Faces German Recall Order Over Element Sequencing Patent Ruling - Yahoo Finance
Illumina, Inc., Formation Bio, Astrazeneca, Merck, and Eli Lilly and Company Expand Billion Cell Atlas Alliance with New Ai Drug Developers - marketscreener.com
Illumina expands Billion Cell Atlas program with new AI drug dev - GuruFocus
Illumina expands Billion Cell Atlas program with new AI drug developers - marketscreener.com
Juno Bio Opens First CLIA-Certified Sequencing Lab Dedicated Entirely to Women's Health, Backed by Ada Ventures, Artesian, Illumina Accelerator, and Entrepreneur First - PR Newswire
Illumina appoints new commercial and legal officers By Investing.com - Investing.com Nigeria
Illumina price tries to gather positive momentumForecast today16-07-2026 - Economies.com
(ILMN) Risk Channels and Responsive Allocation - Stock Traders Daily
Illumina Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Illumina Inc : TD Cowen Raises Target Price t - Moomoo
Illumina and SPT Labtech unveil fireflyGO, enabling faster, simpler targeted oncology research - AOL.com
ILMN5886317 Bond Profile — Key Metrics - TradingView
Video: Illumina gets behind the wheel to drive greater results - Illumina
Element Biosciences Prevails in German Patent Case Against Illumina - Business Wire
Illumina, Inc. Stock 12‑Month Price Target Raised to $165.72, Implies 13% Downside - TradingView
Bioinformatics Services Market Set for Strong Growth Driven - openPR.com
Illumina, Inc. Stock 12‑Month Price Target Raised to $162.94, Implies 14% Downside - TradingView
Illumina builds out C-suite with 2 new execs - MedTech Dive
Illumina Inc (ILMN) Stock Up 3.2% but GF Value Says Overvalued -- GF Score: 72/100 - GuruFocus
Illumina sets July 30 call on second-quarter 2026 results - Stock Titan
Illumina to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026 - marketscreener.com
0.64%
0.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):